CJC-1295 / Ipamorelin

10 mg · Research Blend

CJC-1295 without DAC (MOD GRF 1-29) 5 mg + Ipamorelin 5 mg

10 mg
Presentation

Lyophilized
Form

Research
Blend

Batch documentation
When available

Presentation

$50.00 USD / unit

Quantity

Research Inquiry

Product Overview

A blend of CJC-1295 without DAC (MOD GRF 1-29) and ipamorelin. Its components relate to growth hormone-release pathways; component research does not establish the effects of this blend.

CJC-1295 / Ipamorelin is listed in the EULIX Research catalog as a 10 mg research blend.

The listed formulation combines CJC-1295 without DAC (MOD GRF 1-29) 5 mg + Ipamorelin 5 mg. These quantities describe the nominal presentation; measured results belong to the individual sample report.

Review the product identity, presentation and batch documentation together when consulting analytical documentation.

Research Use Only

For laboratory research and analytical purposes only. Not for human or veterinary use.

Product Specifications

Compound: CJC-1295 / Ipamorelin
Presentation: 10 mg
Composition: CJC-1295 without DAC (MOD GRF 1-29) 5 mg + Ipamorelin 5 mg
Form: Lyophilized material
Storage: Refer to label and batch documentation
Intended Purpose: Research and analytical use only
Brand: EULIX Research

Quality & Testing

Transparency at the Batch Level

Available analytical documentation identifies a specific sample. Review the published report for:

Compound identification
Batch or lot reference
Analytical testing results
Laboratory and report date

Laboratory reports require a confirmed match to the supplied batch. Review the available documents using the COA / Lab Report button.

Scientific Research & References

View All Research

Search independent scientific sources for the listed components. Published research does not validate this product or its batch, and component studies do not establish the properties of this blend.

References checked September 9, 2026. Recent relevant publications are prioritized. Research does not validate EULIX materials or batches.

2026 · Narrative review · component context

Injectable peptides: current orthopaedic research context

January 2026 review discussing CJC-1295 / ipamorelin among other peptides. It does not validate this no-DAC formulation or establish clinical benefit.

Read publication